Pancreatic Cancer Interception Research Team - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Pancreatic Cancer Interception Research Team

SU2C–Lustgarten Foundation For Pancreatic Research Interception Research Team:
Developing Novel Approaches to Treat and Evaluate
Early Pancreatic Cancer

Grant Term: January 2018–December 2021

To intercept pancreatic cancer, the SU2C–Lustgarten Foundation For Pancreatic Research Interception Research Team is taking a comprehensive, two-pronged approach. Team members are testing novel and intensive preoperative treatments allowing doctors to achieve a complete surgical removal of a tumor and eradicate micrometastatic disease in more patients. They are also using organoids-cultured tumor cell colonies―to identify robust biomarkers of response to help guide the choice of standard therapies and immunotherapies.

ABOUT THIS TEAM’S RESEARCH

The SU2C–Lustgarten Foundation Pancreatic Cancer Interception Research Team aims to intercept pancreatic ductal adenocarcinoma through a comprehensive approach that tests intensive preoperative treatments allowing doctors to achieve successful surgery and eradicate micrometastatic disease in more patients, and through the use of organoids to identify robust biomarkers of response to therapy.

Pancreatic cancer can sometimes be cured by surgery, but this is not always successful. Outcomes can be improved by intensive preoperative therapy with FOLFIRINOX, a chemotherapy regimen that combines the drugs 5-fluorouracil, leucovorin, irinotecan hydrochloride, and oxaliplatin. Through a clinical trial, the team is evaluating the addition of losartan, a drug that may enhance the efficacy of FOLFIRINOX. Furthermore, since preliminary data suggest that losartan therapy and radiation therapy alter the immune microenvironment, the team will add immunotherapy to determine if this strategy can provide additional benefit.

The team is also using organoids―tiny colonies of living cells obtained from patients’ tumors prior to starting treatment―to determine if they can be used to predict patients’ response to FOLFIRINOX and other therapies.

This Research Team is part of the SU2C Cancer Interception Initiative, an approach that looks for ways to actively intervene in the formation of the disease rather than treating it only after it is fully developed, and is part of the Pancreatic Cancer Collective portfolio of research.

This team is also part of the Pancreatic Cancer Collective portfolio of research.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.